

Notice of References Cited

Application/Control No.

09/709,170

Applicant(s)/Patent Under
Reexamination
WARRELL ET AL.

Examiner

Terra C. Gibbs

Art Unit

1635

Page 1 of 2

U.S. PATENT DOCUMENTS

*	Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
A	US-			
B	US-			
C	US-			
D	US-			
E	US-			
F	US-			
G	US-			
H	US-			
I	US-			
J	US-			
K	US-			
L	US-			
M	US-			

FOREIGN PATENT DOCUMENTS

*	Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
N					
O					
P					
Q					
R					
S					
T					

NON-PATENT DOCUMENTS

Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)

*		
U	Webb et al. Bcl-2 antisense therapy in patients with non-Hodgkin lymphoma. The Lancet, 1997 vol. 349:1137-1141.	
V	Jansen, B. A Phase I-II Study with Dacarbazine and bcl-2 antisense oligonucleotide G3139 (GENTA) as a chemosensitizer in patients with advanced malignant melanoma. American Society of Clinical Oncology, 1999 Abstract.	
W	Klasa et al. Eradication of Human Non-Hodkin's Lymphoma in SCID mice by Bcl-2 antisense Oligonucleotides combined with lose-dose cyclophosphamide. Clinical Cancer Research, 2000 Vol. 6:2492-2500.	
X	Tortora et al. Cooperative antitumor effect of mixed backbone oligonucleotides targeting protein kinase A in combination with cytotoxic drugs or biologic agents. Antisense and Nucleic acid Drug Development, 1998 Vol. 8:141-145.	

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

Notice of References Cited

Application/Control No.

09/709,170

Applicant(s)/Patent Under
Reexamination
WARRELL ET AL.

Examiner

Terra C. Gibbs

Art Unit

1635

Page 2 of 2

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-			
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)

*		
U	Adjei et al. Docetaxel and Irinotecan, Alone and in combination, in the treatment of non-small cell lung cancer. Seminars in Oncology, 1999 Vol. 26:32-40.	
V	Foran et al. Multicenter Phase II Study of Fludarabine Phosphate for Patients with Newly Diagnosed lymphoplasmacytoid and Mantle-cell lymphoma. Journal of Clinical Oncology, 1999 Vol. 17:546-553.	
W	Murren et al. Dose escalation and pharmacokinetic study of irinotecan in combination with paclitaxel patients with advanced cancer. Cancer Chemotherapy Pharmacology, 2000 Vol. 46:43-50.	
X		

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.